Overview

Tivozanib for Recurrent Glioblastoma

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the study drug tivozanib is still being studied. It also means that the FDA has not yet approved tivozanib for your type of cancer. Tivozanib is an anti-angiogenesis medicine that fights different types of cancer by blocking the blood supply to the tumor, so that the tumor does not receive the nutrients it requires to grow. In this research study, we are looking to see what effects, good and bad, tivozanib will have on you and your disease.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Comprehensive Cancer Network